Associations - HER-2 underexpression

HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval fam-trastuzumab deruxtecan-nxki Sensitive : A1	fam-trastuzumab deruxtecan-nxki Sensitive: A1 - Approval fam-trastuzumab deruxtecan-nxki Sensitive : A1
HER-2 underexpression	Hormone Receptor Positive Breast Cancer	HER-2 underexpression	Hormone Receptor Positive Breast Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: B - Late Trials fam-trastuzumab deruxtecan-nxki Sensitive : B	fam-trastuzumab deruxtecan-nxki Sensitive: B - Late Trials fam-trastuzumab deruxtecan-nxki Sensitive : B
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	eribulin mesylate Sensitive: B - Late Trials eribulin mesylate Sensitive : B	eribulin mesylate Sensitive: B - Late Trials eribulin mesylate Sensitive : B
HER-2 underexpression	Gastroesophageal Junction Adenocarcinoma	HER-2 underexpression	Gastroesophageal Junction Adenocarcinoma	fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label fam-trastuzumab deruxtecan-nxki Sensitive : C1	fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label fam-trastuzumab deruxtecan-nxki Sensitive : C1
HER-2 underexpression	Gastric Cancer	HER-2 underexpression	Gastric Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label fam-trastuzumab deruxtecan-nxki Sensitive : C1	fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label fam-trastuzumab deruxtecan-nxki Sensitive : C1
HER-2 underexpression	Triple Negative Breast Cancer	HER-2 underexpression	Triple Negative Breast Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label fam-trastuzumab deruxtecan-nxki Sensitive : C1	fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label fam-trastuzumab deruxtecan-nxki Sensitive : C1
HER-2 underexpression	Gastric Adenocarcinoma	HER-2 underexpression	Gastric Adenocarcinoma	fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label fam-trastuzumab deruxtecan-nxki Sensitive : C1	fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label fam-trastuzumab deruxtecan-nxki Sensitive : C1
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria ado-trastuzumab emtansine Sensitive : C2	ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria ado-trastuzumab emtansine Sensitive : C2
HER-2 underexpression	Solid Tumor	HER-2 underexpression	Solid Tumor	IKS014 Sensitive: C2 – Inclusion Criteria IKS014 Sensitive : C2	IKS014 Sensitive: C2 – Inclusion Criteria IKS014 Sensitive : C2
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	BNT323 Sensitive: C2 – Inclusion Criteria BNT323 Sensitive : C2	BNT323 Sensitive: C2 – Inclusion Criteria BNT323 Sensitive : C2
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	BL-M07D1 Sensitive: C2 – Inclusion Criteria BL-M07D1 Sensitive : C2	BL-M07D1 Sensitive: C2 – Inclusion Criteria BL-M07D1 Sensitive : C2
HER-2 underexpression	Breast Cancer	HER-2 underexpression	Breast Cancer	SHR-A1811 Sensitive: C2 – Inclusion Criteria SHR-A1811 Sensitive : C2	SHR-A1811 Sensitive: C2 – Inclusion Criteria SHR-A1811 Sensitive : C2

Unlock More with VERI